Latest Breaking News On - Company new drug application - Page 20 : comparemela.com

Galera Therapeutics : Results of Operations and Financial Condition - Form 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 . | February 15, 2023

United statesCompany new drug applicationCompany annual report on formDrug administrationSecurities exchangeGalera therapeutics incFinancial resultsCurrent reportSecurities exchange actExchange actSecurities actNew drug applicationPrescription drug user fee actPrivate securities litigation reform actAnnual reportGalera therapeutics

Form 8-K Galera Therapeutics, For: Feb 15

Form 8-K Galera Therapeutics, For: Feb 15
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCompany new drug applicationCompany annual report on formDrug administrationSecurities exchangeGalera therapeutics incFinancial resultsCash balanceCurrent reportSecurities exchange actExchange actSecurities actNew drug applicationPrescription drug user fee actPrivate securities litigation reform actAnnual report

Eton Pharmaceuticals Inc (ETON) Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection

Eton Pharmaceuticals Inc (ETON) Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Lisam wilsonSean brynjelsenCompany new drug applicationEton pharmaceuticalseton pharmaceuticals incEton pharmaceuticalsDrug administrationSite communications incEton pharmaceuticals nasdaqWall streetNew drug applicationPrescription drug user fee actEton pharmaceuticalseton pharmaceuticalsCarglumic acidBetaine anhydrousIn site communications

Investegate |Minerva Neurosciences, Inc Announcements | Minerva Neurosciences, Inc: Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Investegate announcements from Minerva Neurosciences, Inc, Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Helen shikRemy luthringerFrederick ahlholmMinerva neurosciencesCompany new drug applicationExchange commission onWorld health organizationDrug administrationExchange commissionShik communicationsMinerva neurosciences incMinerva neurosciences announces updateNew drug applicationNegative symptomsExecutive chairmanChief executive officer

Minerva Neurosciences, Inc: Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

BURLINGTON, Mass., Dec. 28, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that

Helen shikRemy luthringerFrederick ahlholmMinerva neurosciencesExchange commissionCompany new drug applicationExchange commission onShik communicationsDrug administrationMinerva neurosciences incNew drug applicationExecutive chairmanChief executive officerPrivate securities litigation reform actQuarterly report